COVID-19 Vaccine

Infectious Diseases
5
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Medigen Vaccine Biologics
5 programs
1
1
2
1
MVC-COV1901Phase 41 trial
MVC-COV1901Phase 31 trial
MVC-COV1901Phase 31 trial
Half dose of MVC-COV1901Phase 21 trial
MVC-COV1901Phase 11 trial
Active Trials
NCT05216601CompletedEst. Nov 2022
NCT05197153CompletedEst. Oct 2022
NCT05426343CompletedEst. Jan 2023
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Medigen Vaccine BiologicsMVC-COV1901
Medigen Vaccine BiologicsMVC-COV1901
Medigen Vaccine BiologicsMVC-COV1901
Medigen Vaccine BiologicsHalf dose of MVC-COV1901
Medigen Vaccine BiologicsMVC-COV1901

Clinical Trials (5)

A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

Start: Oct 2021Est. completion: Jul 2022
Phase 4Unknown

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Start: Jul 2022Est. completion: Mar 2023
Phase 3Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Start: Jul 2022Est. completion: Jan 2023
Phase 3Completed
NCT05197153Medigen Vaccine BiologicsHalf dose of MVC-COV1901

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

Start: Jan 2022Est. completion: Oct 2022
Phase 2Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

Start: May 2022Est. completion: Nov 2022
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space